A coalition of 30 state treasurers, pension funds, and faith-based groups are filing shareholder proposals asking 10 drug makers and distributors to investigate how these companies are responding to the increased business risks caused by the opioid crisis.

In announcing their plans, the coalition noted that drug makers are coming under increasing “legal and legislative scrutiny” for allegedly failing to disclose the addictive potential of opioid painkillers, and that distributors are being pressured to do a better job of reporting suspicious orders to state and federal authorities.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Purdue Pharma is conspicuous in absence here. J&J has been out of the opioid biz for several years, yet are included.
    Overwhelmingly, the volume of Rx’s (and so the most abused opioids) are generics. I see Mylan here, but there are certainly other generic companies heavily involved (like Teva I believe). Again, curious about the rationale for who is included and excluded. Insights to explain would be appreciated.

    • Hi TW,

      I do not know why Teva was not included, however Purdue Pharma is not publicly traded. It is privately owned. The proposals involve publicly traded companies.

      Regards,
      ed at pharmalot

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy